

Systematic Review of Discriminating Power of Outcome Measures Used in Clinical Trials of Fibromyalgia

SERENA F. CARVILLE and ERNEST H.S. CHOY

ABSTRACT. *Objective.* Fibromyalgia (FM) comprises many symptoms and features. Consequently, studies on the condition have used a wide variety of outcome measures and assessment instruments. We investigated those outcome measures and instruments in association with the OMERACT (Outcome measures in Rheumatoid Arthritis Clinical Trials) FM Workshop initiative to define core outcome measures that should be used to assess FM.

Methods. A systematic literature review up to December 2007 was carried out using the keywords “fibromyalgia,” “treatment” or “management,” and “trial.” Data were extracted on outcome measures and assessment instruments used and the pre and post mean and standard deviation to calculate effect sizes (ES). Further sensitivity analysis was carried out according to treatment type, blinding status, and study outcome.

Results. The outcome domains identified fell largely within those defined by OMERACT. Morning stiffness was frequently assessed and therefore has been included here. The number of assessment instruments used was wide-ranging, so sensitivity analysis was only carried out on the top 5 within each domain. ES ranged from 0.54 to 3.77 for the key OMERACT domains. Health-related quality of life (HRQOL) was the only exception that had no instrument with moderate sensitivity. Of the secondary domains, dyscognition was lacking any sensitive instrument, as were fatigue and anxiety in pharmacological trials.

Conclusion. Each of the key OMERACT domains has an instrument that appears to be sensitive to change, with the exception of HRQOL, which requires further research. Dyscognition, fatigue, and anxiety would all benefit from more research into their assessment instruments. (First Release Sept 15 2008; *J Rheumatol* 2008;35:2094–105; doi:10.3899/jrheum.080077)

Key Indexing Terms:

FIBROMYALGIA OUTCOME MEASURES CLINICAL TRIAL SENSITIVITY

Fibromyalgia (FM) is a rheumatologic condition characterized by chronic widespread pain with hyperalgesia and allodynia. Current diagnostic criteria state that pain must have been present for at least 3 months in all 4 quadrants of the body, and pain on palpation at 11 out of 18 predefined tender points¹. FM is associated with a wide range of symptoms including fatigue, sleep disturbance, psychological and cognitive alterations, headache, migraine, variable bowel habits, diffuse abdominal pain, and urinary frequency^{2,3}. Reflecting this, numerous outcome measures have been used in clinical trials resulting in large variations and incon-

sistencies in reporting outcomes. Previous systematic reviews have highlighted these problems in FM clinical trials⁴⁻⁸. Almost all the outcome measures used were not developed for use in FM and few have published psychometric results in FM patient populations.

Through the work of the Outcome Measures for Rheumatoid Arthritis Clinical Trials group (OMERACT), important efficacy outcome domains have been identified independently according to expert opinion and review of major clinical trials as well as clinician and patient Delphi exercises. Starting with a list of 40 potential domains that could be assessed in FM syndrome, the expert Delphi processes involved 3 rounds of voting to prioritize the domains. This was followed by multi-site patient focus groups that again revealed 40 potential domains, which were short-listed and prioritized by 2 rounds of voting among the patient participants. The results from experts and patients were very similar. The short-listed domains included within the “key domains” were pain, patient global, fatigue, health-related quality of life (HRQOL), multidimensional function,

From the Sir Alfred Baring Garrod Clinical Trials Unit, Department of Academic Rheumatology, King's College London, London, UK.

S.F. Carville, PhD; E.H.S. Choy, MD, FRCP, Department of Academic Rheumatology, King's College London.

Address reprint requests to Dr. E.H.S. Choy, Sir Alfred Baring Garrod Clinical Trials Unit, Department of Academic Rheumatology, King's College London, Weston Education Centre, Cutcombe Road, London, SE5 9RJ UK. E-mail: ernest.choy@kcl.ac.uk

Accepted for publication July 12, 2008.

sleep, and depression; and within the “secondary domains,” physical function, tender points, dyscognition (representing “problems with concentration,” “disorganised thoughts,” etc.), and anxiety^{9,10}.

The objectives of OMERACT are to identify and come to a consensus on core sets of domains for rheumatologic conditions, and within these to evaluate the quality of outcome measures used to assess them. This fundamentally includes determining the sensitivity, feasibility, and reliability of instruments. This study aimed to supplement the OMERACT FM work by systematically reviewing outcome instruments that have been used in FM clinical trials. The aim was to map individual instruments to appropriate outcome domains previously identified at OMERACT. The discriminating power of these instruments, a critical aspect of an instrument’s measurement properties, was assessed by their sensitivity to change as measured by effect sizes (ES).

MATERIALS AND METHODS

Search strategy. A systematic review using the key words “fibromyalgia,” “treatment” or “management,” and “trial” for all publications until the end of December 2007 was carried out across a range of databases designed to detect all published clinical trials in fibromyalgia — these were Medline, PubMed, EMBASE, PsycINFO, CINAHL, Web of Sciences, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. A manual search was also undertaken of the bibliographies of trials identified, to verify that all published trials had been detected. Every effort was made to obtain all studies, including those that were not published in English. Where possible, English translations were obtained, or alternatively, assessment and data extraction were performed by native speakers of the respective languages.

Inclusion criteria. Studies were only included if they used the American College of Rheumatology (ACR) 1990 classification criteria for FM¹ to select patients. Studies that included patients with chronic fatigue syndrome or myalgic encephalomyelitis were excluded unless they were divided into separate comparator groups for analysis. The focus of the search was on clinical trials. Reviews were assessed only to verify that all trials had been identified. There was no limitation on quality of study, to ensure that a full range of assessment instruments was included, and also as this would have biased against nonpharmacological studies.

Data extraction. Information for each of the identified reports was tabulated using a custom-made data-extraction form. This included intervention type, randomization (randomised/quasi-randomised or nonrandomised), and blinding status (double-blind/single-blind/open), as well as details of each outcome measure assessed. For each outcome measure, the method of assessment (instrument) was then recorded. Instruments were listed under the outcome measure that the trial reported they had been used for — for example, multi-item assessments may be listed under more than one outcome measure due to their subscales being used for different purposes. The between-group difference was calculated from the mean change between the pre- and post-treatment values for each. When data were available, ES for each instrument within each outcome measure were calculated using these values. Rosnow and Rosenthal’s modified version of the Cohen’s *d* method¹¹ for ES calculation was used:

$$d = \frac{M_1 - M_2}{s_{\text{pooled}}}$$
$$s_{\text{pooled}} = \sqrt{\frac{s_1^2 + s_2^2}{2}}$$

Where *d* = effect size, *M* = mean change, *s* = standard deviation, and 1 and 2 are the treated and controlled groups, respectively. The thresholds used

for interpretation were as follows: values > 0.2 = small, > 0.5 = medium, and > 0.8 = large. If required data were recorded, but either were not presented or were not presented in a suitable format, the author was contacted whenever possible. When the data were provided only in graphic format, if possible these data were extracted and included.

Sensitivity analyses. ES can be influenced by treatment effect and trial design. Ineffective treatment reduces ES, while open-label studies may inflate them. Further, nonpharmacological studies often aim to improve function but may have a smaller effect on pain. Therefore sensitivity analyses were performed to assess whether ES were affected by treatment type (pharmacological and nonpharmacological studies) and blinding and/or randomization status of the study, and excluding studies that had negative overall effect (indication of ineffective treatment or intervention).

RESULTS

Out of 185 trials that were identified (Table 1), outcome measures could be subdivided into 15 domains. Seven of these came under the 8 most important domains that had been identified by OMERACT, a further 3 were considered important, and the remaining 5 did not fit into any of these specific headings. Dyscognition is the only domain identified by OMERACT for which data have not been reported in FM clinical trials, although some studies stated that this was assessed. A full list of outcome domains identified, and the number of different instruments used to assess them, is shown in Figure 1.

Some assessments did not fall clearly within any of the OMERACT domains. These included “Feeling on waking,” assessed by visual analog scale (VAS); “psychological assessments” that did not fit within depression or anxiety (e.g., helplessness, coping strategies, and personality); “associated symptoms” recorded by a variety of means including severity assessed by VAS or Likert scales, symptom diaries, checklists, or by a record of GP visits. Two additional assessments that did not fit in to any subheading were work capacity and knowledge of FM. No further assessment of these miscellaneous domains or instruments was carried out due to the small numbers of each. For domains in which a large number of different instruments had been used, only the top 5 most frequently used assessment instruments were analyzed further (Table 2).

Results for the previously defined key OMERACT domains are given in Table 3. Table 4 shows results for instruments that were included in the secondary OMERACT domains, plus morning stiffness, with the omission of dyscognition. Dyscognition is rarely assessed in clinical trials. In the few trials that assessed dyscognition, none reported the results in a format allowing analysis. “Tender point analysis” was included within “pain”; “function” was grouped under one heading for multidimensional and physical components. “Morning stiffness” was added due to the large number of trials that had considered this outcome. Values shown represent average ES (95% confidence levels), unless stated otherwise.

Table 1. Studies identified for the review.

Nonpharmacological	Class of Treatment		n
	n	Pharmacological	
Aerobic exercise ⁷⁸⁻⁹⁰	11	Selective serotonin reuptake inhibitors ¹⁷⁻²¹	4
Strength training ⁹¹⁻⁹⁴	4	Tricyclic antidepressants ^{18,21-28}	8
Mixed exercise ⁹⁵⁻⁹⁸	4	Dual reuptake inhibitors ^{19,29-33}	5
Pool based ⁹⁹⁻¹⁰³	2	5HT2/3 antagonists ³⁴⁻⁴³	10
Dietary interventions ¹⁰⁴⁻¹¹¹	7	Monoamine oxidase inhibitors ²⁸⁻⁴⁶	4
Cognitive behavioral therapy ¹¹²⁻¹¹⁵ (CBT)	2	Systemic analgesics ⁴⁷⁻⁵²	6
CBT and exercise ¹¹⁶⁻¹²⁰	5	Topical analgesics ⁵³⁻⁵⁵	3
Education ¹²¹⁻¹²⁴	4	Triiodothyronine ⁵⁶⁻⁵⁸	3
Education and exercise ^{95,125-131}	8	Others ⁵⁹⁻⁷⁷	15
Balneotherapy ^{130, 132-34}	4		
Homeopathy ¹³⁵⁻³⁷	3		
Physiotherapy-related ¹³⁸⁻¹⁴⁵	5		
Meditation ¹⁴⁵⁻¹⁴⁷	2		
Laser/light ¹⁴⁸⁻¹⁵¹	2		
Acupuncture ¹⁵²⁻¹⁵⁸	4		
Magnets ^{159,160}	2		
Others ¹⁶¹⁻¹⁹⁴	11		




Figure 1. Outcome measures identified in FM clinical trials and the number of different instruments used to assess them.

Key domains

Pain. The VAS is commonly used and is a sensitive instrument in both pharmacological [0.77 (−0.97, 2.64)] and non-pharmacological trials [0.67 (−2.5, 3.84)]. However, trials differ in the exact question used, varying from “current” and “average over last week” to “average over last month.” Despite controversy about the usefulness of the tender point count in clinical trials (and for diagnosis of FM)^{12,13}, and

suggestions that dolorimetry is a more appropriate measure of tenderness, the results reported here found the tender point count to be sensitive in nonpharmacological trials, with moderate to large ES [0.7 (−1.04, 2.48)]. In pharmacological trials, average ES was small to moderate [0.41 (−1.05, 1.87)], but one single-blind trial reported a large ES [0.77 (−1.57, 3.11)]. However, pressure pain threshold (PPT), measured by dolorimetry, was sensitive only in phar-

Table 2. Top 5 instruments used in the core outcome domains (plus morning stiffness).

Outcome Domain	Instrument	No. of Trials	
Key Domains			
Pain	VAS	112	
	FIQ	42	
	Tender point count	67	
	Myalgic score	39	
	PPT	29	
Patient global	VAS global FM assessment	15	
	VAS global well-being	6	
	VAS global improvement	3	
	Likert global improvement	2	
	Impression of change	3	
Depression	FIQ	36	
	BDI	34	
	Hamilton	12	
	CESD	7	
Fatigue	VAS	7	
	FIQ	34	
	VAS	31	
	Likert 0–4	4	
	CPRS	2	
Quality of life	Multidimensional	2	
	VAS	6	
	SF-36	15	
	ASES	8	
	NHP	3	
Sleep	FAI	3	
	VAS	34	
	FIQ	17	
	No. awakenings	3	
	EEG	4	
Hours of sleep		5	
	Secondary domains		
	Function	FIQ	880
		HAQ	13
		Strength	11
6-min walk		9	
SF-36		12	
Dyscognition	VAS	5	
	CPRS	2	
	Ability to concentrate	1	
	SF-MPQ	1	
	Cognitive difficulties scale	1	
Anxiety	FIQ	35	
	VAS	9	
	STAI	7	
	Beck Anxiety Index	6	
	Hamilton	5	
Clinical global	VAS FM severity	3	
	Severity	6	
	Impression of change	4	
Morning stiffness	VAS general state	2	
	FIQ	38	
	VAS	10	
	Duration (min)	8	
	Likert	3	
CPRS	2		

VAS: visual analog scale, FIQ: Fibromyalgia Impact Questionnaire, PPT: pressure pain threshold, BDI: Beck Depression Inventory, CESD: Centre for Epidemiological Studies Depression scale, CPRS: Comprehensive Psychopathological Rating Scale, SF-36: Short Form-36, ASES: Arthritis Self Efficacy Scale, NHP: Nottingham Health Profile, FAI: Fibromyalgia Attitudes Index, EEG: electroencephalogram, HAQ: Health Assessment Questionnaire, SF-MPQ: short form McGill Pain Questionnaire, STAT: State-Trait Anxiety index.

macological trials [3.77 (2.73, 3.82)], based on 2 trials, and had low sensitivity in nonpharmacological trials [0.09 (–1.34, 2.34)].

Patient global assessment. Patient global assessment was commonly assessed by VAS. It was sensitive to change across all trials [pharmacological, 1.01 (–0.31, 2.34); non-pharmacological, 0.48 (–0.54, 1.51)]. Other instruments were studied less extensively.

Depression. Both the Hamilton scale and Centre for Epidemiologic Studies Depression scale (CESD) appeared to be sensitive in pharmacological studies [0.72 (–1.7, 3.14) and 1.4 (0.36, 2.43) respectively], although with further analysis it seemed that the sensitivity of the Hamilton was inflated by 2 single-blind studies, and the CESD results were based on only one trial. The Beck Depression Inventory (BDI) in nonpharmacological trials was sensitive to change [0.9 (–2.33, 4.13)]; however, this was based on data from only single-blind and open-label studies. The ES of the BDI appeared to be smaller in pharmacological trials [0.19 (–3.44, 3.82)]. Recently, many pharmacological studies have excluded patients with significant depression; this could have resulted in underestimation of the performance of these instruments as baseline depression scores in these studies would have been low.

Fatigue. The VAS and Likert scales for nonpharmacological trials had good sensitivity for fatigue [1.3 (–0.08, 2.68) and 1.09 (–0.53, 1.65), respectively]. VAS were predominantly used in pharmacological trials, with an ES of 0.34 (–0.94, 1.63).

Health-related quality of life. There was no instrument that was particularly sensitive to change for HRQOL. The physical and mental component summary scores from the Short Form-36 (SF-36) health survey were reported only in pharmacological trials, with the physical component gaining the most support (of all subscales) for pharmacological studies [0.43 (–1.59, 2.44)], although this was based on only 2 studies. Results from all of the 8 subscales are available in both pharmacological and nonpharmacological trials; however, all have low sensitivity (range 0.002–0.32, role limitation physical, nonpharmacological and pharmacological, respectively) and are based on only a very small number of studies (maximum of 3).

Sleep. The VAS scale may be moderately useful across trials for sleep assessment [pharmacological, 0.54 (–1.03, 2.12); nonpharmacological, 0.43 (–0.92, 1.7)]; and the Fibromyalgia Impact Questionnaire (FIQ) sleep item was sensitive in nonpharmacological trials [0.51 (–1.21, 2.23)], although based on mainly single-blind studies.

Function. When the overall FIQ score was used as a measure of function it was moderately sensitive across trials, with smaller effect seen in pharmacological trials versus non-pharmacological trials [pharmacological, 0.45 (–7.12, 8.02); nonpharmacological, 0.52 (–4.31, 5.36)]. In single-blind trials in pharmacological trials the sensitivity was good [phar-

Table 3. Effect sizes (ES) for selected instruments used within the key OMERACT domains: Pain, Patient global, Depression, Fatigue, Quality of life, Sleep, and Function. Results reported as mean ES (95% confidence levels); n = number of trials averaged.

OMERACT Instrument Domain		Pharmacological ES			Nonpharmacological ES			Open
		Average	Double-blind	Single-blind/ open	Average	Double-blind	Single-blind	
Pain	VAS	0.77 (-0.97, 2.64) n = 23	0.77 (-0.97, 2.64) n = 23	—	0.67 (-2.5, 3.84) n = 36	1.1 (-0.16, 2.36) n = 6	0.51 (-2.42, 3.44) n = 8	0.7 (-2.88, 4.29) n = 20
	FIQ	0.33 (-0.14, 0.8) n = 1	0.33 (-0.14, 0.8) n = 1	—	0.57 (-0.56, 1.69) n = 10	—	1.04 (-0.17, 2.24) n = 4	0.31 (-0.72, 1.35) n = 4
	Tender point count	0.41 (-1.05, 1.87) n = 13	0.29 (-1.08, 1.67) n = 12	0.77 (-1.57, 3.11) n = 1	0.7 (-1.04, 2.48) n = 23	3.2 (1.71, 4.69) n = 3	0.6 (-1.29, 2.5) n = 8	0.14 (-1.6, 1.86) n = 12
	PPT	3.77 (3.73, 3.82) n = 2	3.77 (3.73, 3.82) n = 2	—	0.09 (-1.34, 2.34) n = 11	0.11 (-0.37, 0.6) n = 4	0.07 (-7.28, 7.41) n = 2	0.3 (-0.13, 0.73) n = 3
Patient global	VAS global FM assessment	1.01 (-0.31, 2.34) n = 6	1.01 (-0.31, 2.34) n = 6	—	0.48 (-0.54, 1.51) n = 1	—	0.48 (-0.54, 1.51) n = 1	—
	Depression FIQ depression subscale	0.4 (-0.79, 1.59) n = 3	0.4 (-0.79, 1.59) n = 3	—	0.01 (-1.55, 1.53) n = 10	-0.18 (-1.63, 1.27) n = 2	0.21 (-1.5, 1.93) n = 2	0.03 (-1.54, 1.49) n = 6
	BDI	0.19 (-3.44, 3.82) n = 5	0.19 (-3.44, 3.82) n = 5	—	0.9 (-2.33, 4.13) n = 14	—	0.54 (-3.82, 4.9) n = 7	1.26 (-0.84, 3.36) n = 7
	Hamilton	0.72 (-1.7, 3.14) n = 5	0.26 (-2.35, 2.87) n = 3	1.41 (-0.73, 3.56) n = 2	0.45 (-3.34, 4.24) n = 3	—	0.47 (-3.88, 4.82) n = 2	0.4 (-2.26, 3.07) n = 1
Fatigue	CESD	1.4 (0.36, 2.43) n = 2	1.4 (0.36, 2.43) n = 2	—	0.12 (-2.76, 2.99) n = 11	—	—	0.12 (-2.76, 2.99) n = 7
	FIQ fatigue subscale	0.12 (-0.43, 0.67) n = 2	0.12 (-0.43, 0.67) n = 2	—	0.3 (-0.9, 1.5) n = 3	0.23 (-0.88, 1.34) n = 1	0.75 (-0.91, 2.42) n = 1	0.19 (-0.9, 1.29) n = 1
	VAS	0.34 (-0.94, 1.63) n = 10	0.34 (-0.94, 1.63) n = 10	—	1.3 (-0.08, 2.68) n = 3	2.66 (2.18, 3.13) n = 1	0.51 (-1.01, 2.04) n = 1	0.72 (-1.43, 2.87) n = 1
	Likert 0–4	—	—	—	1.09 (0.53, 1.65) n = 3	—	1.09 (0.53, 1.65) n = 3	—
Quality of life	SF-36 physical component	0.43 (-1.59, 2.44) n = 2	0.43 (-1.59, 2.44) n = 2	—	—	—	—	—
	SF-36 mental component	0.18 (-2.88, 3.24) n = 2	0.18 (-2.88, 3.24) n = 2	—	—	—	—	—
	ASES	—	—	—	0.39 (-8.1, 8.87) n = 9	—	—	0.39 (-8.1, 8.87) n = 9
Sleep	VAS	0.54 (-1.03, 2.12) n = 9	0.54 (-1.03, 2.12) n = 9	—	0.43 (-0.92, 1.7) n = 3	1.01 (0.45, 1.56) n = 1	-0.05 (-1.62, 1.53) n = 1	0.32 (-1.6, 2.34) n = 1
	FIQ sleep subscale	0.26 (-0.91, 1.43) n = 3	0.26 (-0.91, 1.43) n = 3	—	0.51 (-1.2, 2.23) n = 5	0.15 (-1.29, 2.23) n = 1	0.75 (-0.73, 2.22) n = 3	0.16 (-2.59, 2.91) n = 1
Function	FIQ physical function subscale	0.45 (-7.12, 8.02) n = 17	0.53 (-7.5, 8.56) n = 16	0.96 (-3.87, 5.78) n = 1	0.52 (-4.31, 5.36) n = 39	0.58 (-6.64, 7.6) n = 6	0.67 (-6.4, 7.73) n = 10	0.65 (-2.64, 3.95) n = 23
	HAQ	-0.08 (-0.66, 0.49) n = 4	-0.08 (-0.66, 0.49) n = 4	—	0.6 (0.28, 0.92) n = 2	—	0.59 (0.37, 0.81) n = 1	0.6 (0.19, 1.02) n = 1

VAS: visual analog scale, FIQ: Fibromyalgia Impact Questionnaire, PPT: pressure pain threshold, BDI: Beck Depression Inventory, CESD: Centre for Epidemiologic Studies Depression scale, SF-36: Short form-36, ASES: Arthritis Self Efficacy Scale, HAQ: Health Assessment Questionnaire.

macological, 0.96 (-3.87, 5.78)], but these were not well controlled studies, so the ES may have been biased. The 6-minute walk may be of some use in nonpharmacological studies [0.6 (-40.98, 42.18)], although these data were collected from uncontrolled studies and the confidence levels were very wide.

Secondary domains

Anxiety. The VAS and the State-Trait Anxiety Inventory

(STAI) were both sensitive in nonpharmacological trials [0.81 (-0.87, 2.5) and 1.32 (-5.35, 7.98), respectively]; however, these results were each from 2 uncontrolled trials. There did not appear to be a sensitive measure for pharmacological interventions, although again the small number of assessments of this measure require more attention before firm conclusions can be reached on the performance of the existing instruments.

Clinician global. The assessment of clinical global impres-

Table 4. Effect sizes (ES) for the top 5 instruments used within 2 of the secondary OMERACT domains: Anxiety and Clinician Global plus Morning Stiffness. Results reported as mean ES (95% confidence levels); n = number of trials averaged.

OMERACT Instrument Domain	Average	Pharmacological ES			Nonpharmacological ES			Open
		Double-blind	Single-blind/ Open	Average	Double-blind	Single-blind		
Anxiety	FIQ anxiety subscale	0.2 (-1.05, 1.46) n = 3	0.2 (-1.05, 1.46) n = 3	—	0.09 (-1.48, 1.66) n = 11	-0.18 (-1.59, 1.22) n = 2	-0.4 (-2.41, 1.6) n = 1	0.22 (-1.34, 1.78) n = 8
	VAS	—	—	—	0.81 (-0.87, 2.5) n = 2	—	—	0.81 (-0.87, 2.5) n = 2
	STAI	0.03 (-5.83, 5.9) n = 1	0.03 (-5.83, 5.9) n = 1	—	1.32 (-5.35, 7.98) n = 2	—	—	1.32 (-5.35, 7.98) n = 2
	Beck anxiety index	0.22 (-3.06, 3.5) n = 2	0.22 (-3.06, 3.5) n = 2	—	0.08 (-7.25, 7.42) n = 1	—	0.08 (-7.25, 7.42) n = 1	—
Clinician global	VAS FM severity	0.19 (-0.2, 0.58) n = 2	0.19 (-0.2, 0.58) n = 2	—	0.12 (-0.58, 0.82) n = 2	—	—	0.12 (-0.58, 0.82) n = 2
	Severity, 1-7 scale	0.26 (-0.87, 1.4) n = 4	0.26 (-0.87, 1.4) n = 4	—	—	—	—	—
	Impression of change	0.37 (-0.18, 0.93) n = 2	0.37 (-0.18, 0.93) n = 2	—	—	—	—	—
	VAS general state	—	—	—	-3.84 (-4.02, -3.67) n = 1	-3.84 (-4.02, -3.67) n = 1	—	—
Morning stiffness	FIQ stiffness subscale	0.27 (-0.83, 1.37) n = 4	0.27 (-0.83, 1.37) n = 4	—	0.26 (-0.89, 1.41) n = 12	0.27 (-0.98, 1.52) n = 2	-0.69 (-2.42, 1.05) n = 1	0.36 (-0.7, 1.42) n = 9
	VAS	—	—	—	-0.53 (-2.62, 1.55) n = 1	—	—	-0.53 (-2.62, 1.55) n = 1
	Duration (min)	0.34 (-9.35, 10.02) n = 3	0.44 (-10.98, 11.87) n = 2	0.13 (-6.07, 6.33) n = 1	1.41 (-4.64, 7.46) n = 1	1.41 (-4.64, 7.46) n = 1	—	—
	Likert	0.67 (0.22, 1.12) n = 1	—	0.67 (0.22, 1.12) n = 1	0.63 (0.12, 1.45) n = 3	0.08 (-0.43, 0.59) n = 1	0.91 (0.39, 1.42) n = 2	—

FIQ: Fibromyalgia Impact Questionnaire, VAS: visual analog scale, STAI: State-Trait Anxiety Inventory.

sion was a common endpoint in FM studies; however, in recent years this outcome assessment has been dropped in favor of a reliance on the patient as the best reporter of his or her improvement or worsening, particularly as it relates to the inherently subjective measure of pain. Therefore only a few ES calculations are available for this endpoint (Table 3).

Morning stiffness. These results suggest that there are sensitive instruments available for both pharmacological and nonpharmacological studies. Duration had large ES in nonpharmacological studies [1.41 (-4.64, 7.46)], and the VAS and Likert scales may be moderately sensitive [0.53 (-2.62, 1.55) and 0.63 (0.12, 1.45), respectively], but the VAS data were from uncontrolled trials. Likert scales were also moderately sensitive in pharmacological interventions [0.67 (0.22, 1.12)], although this was from just one uncontrolled study.

Sensitivity analyses

The results from the analysis only of effective treatments did not alter the findings substantially. There were some notable exceptions that improved in sensitivity, although these were mainly in nonpharmacological trials based on uncontrolled studies. The only one within the pharmacological trials was the tender point count, which appeared to be slightly more

sensitive, increasing from low to moderate sensitivity [0.53 (-0.98, 2.04)] and high sensitivity in nonpharmacological, including double-blind trials [1.68 (0.47, 3.3)]. Excluding negative studies can also inflate the ES and introduces a dissemination bias. For these reasons, we have reported results with all included studies.

ES can be inflated by including open-label studies. Indeed, sensitivity analysis excluding these trials showed that the average ES of the Hamilton scale for depression [double-blind, 0.26 (-2.35, 2.87); uncontrolled, 1.41 (-0.73, 3.56)], tender point count for pain [double-blind, 0.29 (-1.08, 1.67); uncontrolled, 0.77 (-1.57, 3.11)], and FIQ for function [double-blind, 0.53 (-7.5, 8.56); uncontrolled, 0.96 (-3.87, 5.78)] all seemed to be inflated by including uncontrolled open-label trials. However, it is important to note that it is not possible for all nonpharmacological trials to be double-blind, or even single-blind in some cases.

DISCUSSION

This systematic literature review highlighted the vast number of outcome measures that have been used in FM clinical trials. Compounded by inconsistencies in reporting results in publications, the argument for the need to develop a glob-

al consensus on core outcome domains to be used in all clinical trial is overwhelming.

The aim of our review was not to compare instruments to one another, but to identify whether or not there were assessment instruments currently being used that were sensitive to change across treatments in FM. Our results indicated that for each of the outcome domains identified by OMERACT 8 (with the exception of dyscognition and HRQOL), there is at least one instrument that is discriminatory. Pain, patient global, sleep, depression, and function all had instruments that were at least moderately sensitive in either pharmacological or nonpharmacological interventions. These results are promising for outcome assessment in FM. This review was not able to examine sensitivity analyses for all instruments, and consequently some were omitted due to our limit of assessing only the top 5 most widely used, and there may be more sensitive instruments that were not examined here. We also limited studies to those that used the ACR 1990 criteria¹; using a wider range of diagnosis classification may have resulted in more information being gained.

Interpreting ES is not straightforward. It can be influenced by a number of factors, including study design, patient population, and treatment efficacy. Open-label studies can inflate the ES and ineffective treatments reduce it. Our sensitivity analyses showed that in current FM trials, the former is indeed the case. Therefore in cases where data are available only from uncontrolled studies the results should be interpreted with caution. However, in the nonpharmacological studies, despite uncontrolled studies being more common, many discriminatory instruments (VAS for pain, fatigue and sleep; FIQ for function; and duration of morning stiffness) are validated in double-blinded trials.

In many trials, especially pharmacological studies, patients with significant depression were excluded. With low baseline depression scores in these studies, the likelihood of change is reduced and may underestimate the discriminatory power of instruments that measure depression. The Hamilton scale for depression did prove to be relatively sensitive to change in both pharmacological and nonpharmacological trials, as was the BDI for the nonpharmacological trials. All the pharmacological trials that provided results for the Hamilton, except one, did not exclude depressed patients. This suggests that outcome measures may be more sensitive to change when appropriate populations are included such that they have impairment of the domains that the instrument was designed to measure.

For assessment of VAS, all time-ranges were included, e.g., current, worst, average over last week, etc. Further research will be necessary to determine which time period is the most appropriate to use for the corresponding outcome measures in clinical trials.

FM is characterized by manifold symptoms. Some treatments target specific features such as exercise to improve function, which has resulted in mixed reports on influence

on pain. By pooling all the studies, it is likely that we have underestimated the discriminatory power of these instruments. It has also been suggested that there are different subgroups of patients with FM displaying different symptom profiles¹⁴, and consequently responding to different treatments. This may also lead to an underestimation of ES.

According to this work, single-item assessments consistently appeared to have greater discriminative properties than multi-item assessments. This may be because single-item assessments have been used more commonly than multiple-items assessments. Also, reliability is directly related to the number of items within a scale, so single-item assessments can be of lower reliability and consequently limited validity. Thus it is important not to rule out multi-item assessments when choosing the right instrument for any particular study.

This work supports results from the previous OMERACT workshop on the main outcome domains recommended to be considered for inclusion in the core data set¹⁵. The notable exception was “morning stiffness,” which was ranked highly for importance by patients but not experts¹⁶. Interestingly, morning stiffness was commonly measured and was assessed by relatively few instruments (8), so reporting was fairly consistent.

This work also revealed that further research is needed to develop validated and sensitive instruments to assess dyscognition. HRQOL, anxiety, and fatigue would also benefit from more research to develop more sensitive instruments, and morning stiffness as an outcome domain. Finally, while important, discrimination is only one of the key measurement properties to consider in instrument selection. Other properties, such as validity and reliability and how the instrument fits into the overall conceptual framework, must also be considered — further work to assess these additional properties is called for.

ACKNOWLEDGMENT

The authors acknowledge Susan Martin for her input to this work, and the OMERACT Fibromyalgia Group.

REFERENCES

1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. *Arthritis Rheum* 1990;33:160-72.
2. Hudson JI, Goldenberg DL, Pope HG Jr, Keck PE Jr, Schlessinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. *Am J Med* 1992;92:363-7.
3. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. *J Rheumatol* 2005;32:2270-7.
4. Busch A, Schachter CL, Peloso PM, Bombardier C. Exercise for treating fibromyalgia syndrome. *Cochrane Database System Rev* 2002;3.
5. Sim J, Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. *Clin J Pain* 2002;18:324-36.
6. Baker K, Barkhuizen A. Pharmacologic treatment of fibromyalgia. *Curr Pain Headache Rep* 2005;9:301-6.
7. Crofford LJ, Appleton BE. The treatment of fibromyalgia: a review of clinical trials. *Curr Rheumatol Rep* 2000;2:101-3.

8. Rossey LA, Buckelew SP, Dorr N, et al. A meta-analysis of fibromyalgia treatment interventions. *Ann Behav Med* 1999;21:180-91.
9. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. *J Rheumatol* 2005;32:2270-7.
10. Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. *J Rheumatol* 2007;34:1415-25.
11. Rosnow RL, Rosenthal R. Computing contrasts, effect sizes, and counternulls on other people's published data: General procedures for research consumers. *Psychol Methods* 1996;1:331-40.
12. Harden NR, Revivo G, Song S, et al. A critical analysis of the tender points in fibromyalgia. *Pain Med* 2007;8:147-56.
13. Petzke F, Gracely RH, Park KM, Ambrose K, Clauw DJ. What do tender points measure? Influence of distress on 4 measures of tenderness. *J Rheumatol* 2003;30:567-74.
14. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. *Arthritis Rheum* 2003;48:2916-22.
15. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. *J Rheumatol* 2005;32:2270-7.
16. Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. *J Rheumatol* 2007;34:1415-25.
17. Norregaard J, Volkman H, Danneskiold-Samsøe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. *Pain* 1995;61:445-9.
18. Kee WG, Smith AR, Folk JW. Citalopram in the treatment of fibromyalgia. *J Back Musculoskel Rehabil* 2004;17:117-25.
19. Patkar AA, Masand PS, Krulwicz S, et al. A randomized, controlled trial of controlled release paroxetine in fibromyalgia. *Am J Med* 2007;120:448-54.
20. Carette S, Bell MJ, Reynolds WJ et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. *Arthritis Rheum* 1994;37:32-40.
21. Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. *Arthritis Rheum* 1995;38:1211-7.
22. Ginsberg F, Mancaux A, Joos E, Vanhove P, Famaey J-P. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. *J Musculoskel Pain* 1996;4:37-47.
23. Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. *Clin Exp Rheumatol* 2001;19:697-702.
24. Capaci K, Hegguler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. *Pain Clinic* 2002;14:223-8.
25. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. *Arthritis Rheum* 1996;39:1852-9.
26. Giordano N, Geraci S, Santacrose C, Mattii G, Battisti E, Gennari C. Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: A single-blind study. *Curr Ther Res Clin Exp* 1999;60:696-702.
27. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. *Br J Rheumatol* 1998;37:1279-86.
28. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. *Arthritis Rheum* 2004;50:2974-84.
29. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. *Pain* 2005;119:5-15.
30. Nagaoka S, Ohno M, Sekiguchi A. An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms. *Int J Psychiatr Clin Pract* 2004;8:47-51.
31. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. *Int J Clin Pharmacol Res* 2004;19:S27-S35.
32. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. *Ann Pharmacother* 2003;37:1561-5.
33. Evren B, Evren C, Guler MH. An open clinical trial of venlafaxine in the treatment of pain, depressive and anxiety symptoms in fibromyalgia. *Pain Clinic* 2006;18:167-73.
34. Farber L, Stratz T, Bruckle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia — A highly selective and competitive 5-HT₃ receptor antagonist. *Scand J Rheumatol Suppl* 2000;29:49-54.
35. Haus U, Varga B, Stratz T, Spath M, Muller W. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. *Scand J Rheumatol* 2000;113:55-8.
36. Hrycaj P, Stratz T, Mennet P, Muller W. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome — A preliminary study. *J Rheumatol* 1996;23:1418-23.
37. Müller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. *Scand J Rheumatol* 2000;29:59-62.
38. Olin R, Klein R, Berg PA. A randomised double-blind 16-week study of Ritanserin in fibromyalgia syndrome: Clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids. *Clin Rheumatol* 1998;17:89-94.
39. Samborski W, Stratz T, Lacki JK, Klama K, Mennet P, Muller W. The 5-HT₃ blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose. *Mater Med Pol* 1996;28:17-9.
40. Samborski W, Lezanska-Szpera M, Rybakowski JK. Effects of antidepressant mirtazapine on fibromyalgia symptoms. *Rocz Akad Med Białymst* 2004;49:265-9.
41. Samborski W, Lezanska-Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. *Pharmacopsychiatry* 2004;37:168-70.
42. Spath M, Stratz T, Neeck G, et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. *Scand J Rheumatol* 2004;33:267-70.
43. Stratz T, Farber L, Varga B, Haus U, Baumgartner C, Muller W. Treatment of fibromyalgia with intravenous application of tropisetron. *J Musculoskel Pain* 2000;8:31-40.
44. Ginsberg F, Joos E, Geczy J, Bruhwyler J, Vandekerckhove K, Famaey JP. A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. *J Musculoskel Pain* 1998;6:5-17.
45. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. *Adv Exp Med Biol* 1996;398:373-9.
46. Yavuzer G, Kucukdeveci A, Arasil T, Elhan A. Moclobemid treatment in primary fibromyalgia syndrome. *Eur J Phys Med Rehabil* 1998;8:35-8.
47. Graven-Nielsen T, Aspegren KS, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. *Pain* 2000;85:483-91.
48. McClean G. Does intravenous lidocaine reduce fibromyalgia pain?: A randomized, double-blind, placebo controlled cross-over study.

- Pain Clinic 2000;12:181-5.
49. Raphael JH, Southall JL, Treharne GJ, Kitas GD. Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome. *BMC Musculoskelet Disord* 2002;3:21.
 50. Russell J, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. *J Clin Rheumatol* 2000;6:250-7.
 51. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. *Scand J Rheumatol* 1995;24:360-5.
 52. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. *Am J Med* 2003;114:537-45.
 53. Scudds RA, Janzen V, Delaney G, et al. The use of topical 4% lidocaine in sphenopalatine ganglion blocks for the treatment of chronic muscle pain syndromes: a randomized, controlled trial. *Pain* 1995;62:69-77.
 54. Janzen VD, Scudds R. Sphenopalatine blocks in the treatment of pain in fibromyalgia and myofascial pain syndrome. *Laryngoscope* 1997;107:1420-2.
 55. McCarty DJ, Csuka M, McCarthy G, Trotter D. Treatment of pain due to fibromyalgia with topical capsaicin: A pilot study. *Semin Arthritis Rheum* 1994;23:41-7.
 56. Lowe JC, Garrison RL, Reichman AJ, Yellin J, Thompson M, Kaufman D. Effectiveness and safety of T3 (Triiodothyronine) therapy for euthyroid fibromyalgia: A double-blind placebo-controlled response-driven crossover study. *Clin Bull Myofascial Ther* 1997;2:31-57.
 57. Lowe JC, Reichman AJ, Yellin J. The process of change during T3 treatment for euthyroid fibromyalgia: A double-blind placebo-controlled crossover study. *Clin Bull Myofascial Ther* 1997;2:91-124.
 58. Lowe JC, Garrison RL, Reichman AJ, Yellin J. Triiodothyronine (T3) treatment of euthyroid fibromyalgia: A small-N replication of a double-blind placebo-controlled crossover study. *Clin Bull Myofascial Ther* 1997;2:71-88.
 59. Zachrisson O, Regland B, Jahreskog M, Jonsson M, Kron M, Gottfries CG. Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome — a randomised controlled trial. *Eur J Pain* 2002;6:455-66.
 60. Andersson M, Bagby JR, Dyrehag L-E, Gottfries C-G. Effects of staphylococcus toxoid vaccine on pain and fatigue in patients with fibromyalgia/chronic fatigue syndrome. *Eur J Pain* 1998;2:133-42.
 61. Paulson GW, Gill W. Botulinum toxin is unsatisfactory therapy for fibromyalgia. *Mov Disord* 1996;11:459.
 62. Kendall SA, Schaadt ML, Graff LB, et al. No effect of antiviral (valacyclovir) treatment in fibromyalgia: a double blind, randomized study. *J Rheumatol* 2004;31:783-4.
 63. Bessette L, Carette S, Fossel AH, Lew RA. A placebo controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia. *Scand J Rheumatol* 1998;27:112-6.
 64. Citera G, Arias MA, Maldonado-Cocco JA, et al. The effect of melatonin in patients with fibromyalgia: A pilot study. *Clin Rheumatol* 2000;19:9-13.
 65. McLain D. An open label dose finding trial of tizanidine [Zanaflex] for treatment of fibromyalgia. *J Musculoskel Pain* 2002;10:7-18.
 66. Moldofsky H, Lue FA, Mously C, Roth-Schechter B, Reynolds WJ. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. *J Rheumatol* 1996;23:529-33.
 67. Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J, et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. *Pain* 1996;65:221-5.
 68. Rico-Villademoros F, Hidalgo J, Dominguez I, Garcia-Leiva JM, Calandre EP. Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine. *Prog Neuropsychopharmacol Biol Psychiatry* 2005;29:161-4.
 69. Russell IJ, Michalek JE, Flechas JD, Abraham GE. Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. *J Rheumatol* 1995;22:953-8.
 70. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. *J Rheumatol* 2003;30:1070-4.
 71. Volkmann H, Norregaard J, Jacobsen S, Danneskiold-Samsøe B, Knoke G, Nehrlich D. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. *Scand J Rheumatol* 1997;26:206-11.
 72. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. *Am J Med* 1998;104:227-31.
 73. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2005;52:1264-73.
 74. Teitelbaum JE, Bird B, Greenfield RM, Weiss A, Muenz L, Gould L. Effective treatment of chronic fatigue syndrome and fibromyalgia — A randomized, double-blind, placebo-controlled, intent-to-treat study. *J Chronic Fatigue Syndr* 2001;8:3-28.
 75. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. *Arthritis Rheum* 2005;52:2495-505.
 76. Finckh A, Berner IC, Aubry-Rozier B, So AKL. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. *J Rheumatol* 2005;32:1336-40.
 77. Wood PB, Kablinger AS, Caldito GS. Open trial of pindolol in the treatment of fibromyalgia. *Ann Pharmacother* 2005;39:1812-6.
 78. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. *Arthritis Rheum* 2007;56:1336-44.
 79. Mengshoel AM, Forseth KO, Haugen M, Walle-Hansen R, Forre O. Multidisciplinary approach to fibromyalgia. A pilot study. *Clin Rheumatol* 1995;14:165-70.
 80. Norregaard J, Lykkegaard JJ, Mehlsen J, Danneskiold-Samsøe B. Exercise training in treatment of fibromyalgia. *J Musculoskel Pain* 1997;5:71-9.
 81. Nichols D, Glenn DS. Effects of aerobic exercise on pain perception, affect and level of disability in individuals with fibromyalgia. *Phys Ther* 1994;74:327-32.
 82. Ramsay C, Moreland J, Ho M, Joyce S, Waker S, Pullar T. An observer-blinded comparison of supervised and unsupervised aerobic exercise regimens in fibromyalgia. *Rheumatology Oxford* 2000;39:501-5.
 83. Schachter CL, Busch AJ, Peloso PM, Sheppard MS. Effects of short versus long bouts of aerobic exercise in sedentary women with fibromyalgia: a randomized controlled trial. *Phys Ther* 2003;83:340-58.
 84. Richards SC, Scott DL. Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial. *BMJ* 2002;325:185-8.
 85. Gowans SE, deHueck A, Voss S, Silaj A, Abbey SE, Reynolds WJ. Effect of a randomized, controlled trial of exercise on mood and physical function in individuals with fibromyalgia. *Arthritis Rheum* 2001;45:519-29.
 86. Van Santen M, Bolwijn P, Verstappen F, et al. A randomized clinical

- trial comparing fitness and biofeedback training versus basic treatment in patients with fibromyalgia. *J Rheumatol* 2002;29:575-81.
87. Van Santen M, Bolwijn P, Landewe R, et al. High or low intensity aerobic fitness training in fibromyalgia: does it matter? *J Rheumatol* 2002;29:582-7.
 88. Da Costa D, Abrahamowicz M, Lowensteyn I, et al. A randomized clinical trial of an individualized home-based exercise programme for women with fibromyalgia. *Rheumatology Oxford* 2005;44:1422-7.
 89. Meyer BB, Lemley KJ. Utilizing exercise to affect the symptomatology of fibromyalgia: a pilot study. *Med Sci Sports Exerc* 2000;32:1691-7.
 90. Dobkin PL, Da Costa D, Abrahamowicz M, et al. Adherence during an individualized home based 12-week exercise program in women with fibromyalgia. *J Rheumatol* 2006;33:333-41.
 91. Bojner HE, Kowalski J, Theorell T, Anderberg UM. Dance/movement therapy in fibromyalgia patients: Changes in self-figure drawings and their relation to verbal self-rating scales. *Arts in Psychotherapy* 2006;33:11-25.
 92. Jones KD, Burckhardt CS, Clark SR, Bennett RM, Potempa KM. A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia. *J Rheumatol* 2002;29:1041-8.
 93. Geel SE, Robergs RA. The effect of graded resistance exercise on fibromyalgia symptoms and muscle bioenergetics: A pilot study. *Arthritis Care Res* 2002;47:82-6.
 94. Hakkinen A, Hakkinen K, Hannonen P, Alen M. Strength training induced adaptations in neuromuscular function of premenopausal women with fibromyalgia: Comparison with healthy women. *Ann Rheum Dis* 2001;60:21-6.
 95. Kingsley JD, Panton LB, Toole T, Sirithienthad P, Mathis R, McMillan V. The effects of a 12-week strength-training program on strength and functionality in women with fibromyalgia. *Arch Phys Med Rehabil* 2005;86:1713-21.
 96. Bailey A, Starr L, Alderson M, Moreland J. A comparative evaluation of a fibromyalgia rehabilitation program. *Arthritis Care Res* 1999;12:336-40.
 97. Dawson KA, Tiidus PM, Pierrynowski M. Evaluation of a community-based exercise program for diminishing symptoms of fibromyalgia. *Physiother Can* 2003;55:17-22.
 98. Isomeri R, Mikkelsen M, Latikka P, Kammonen K. Effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia. *J Musculoskel Pain* 1993;1:253-60.
 99. Martin L, Nutting A, MacIntosh BR, Edworthy SM, Butterwick D, Cook J. An exercise program in the treatment of fibromyalgia. *J Rheumatol* 1996;23:1050-3.
 100. Altan L, Bingol U, Aykac M, Koc Z, Yurtkuran M. Investigation of the effects of pool-based exercise on fibromyalgia syndrome. *Rheumatol Int* 2004;24:272-7.
 101. Jentoft ES, Kvalvik AG, Mengshoel M. Effects of pool-based and land-based aerobic exercise on women with fibromyalgia/chronic widespread muscle pain. *Arthritis Care Res* 2001;45:42-7.
 102. Assis MR, Silva LE, Barros Alves AM, et al. A randomized controlled trial of deep water running: Clinical effectiveness of aquatic exercise to treat fibromyalgia. *Arthritis Rheum* 2006;55:65.
 103. Gusi N, Tomas-Carus P, Hakkinen A, Hakkinen K, Ortega-Alonso A. Exercise in waist-high warm water decreases pain and improves health-related quality of life and strength in the lower extremities in women with fibromyalgia. *Arthritis Rheum* 2006;55:66-72.
 104. Vitorino DFM, Carvalho LBC, Prado GF. Hydrotherapy and conventional physiotherapy improve total sleep time and quality of life in fibromyalgia patients: Randomized clinical trial. *Sleep Med* 2006;7:293-6.
 105. Azad KA, Alam MN, Haq SA, et al. Vegetarian diet in the treatment of fibromyalgia. *Bangladesh Med Res Counc Bull* 2000;26:41-7.
 106. Bramwell B, Ferguson S, Scarlett N, Macintosh A. The use of ascorbin in the treatment of fibromyalgia patients: a preliminary trial. *Altern Med Rev* 2000;5:455-62.
 107. Edwards AM, Blackburn L, Christie S, Townsend S, David J. Food supplements in the treatment of primary fibromyalgia: A double-blind, crossover trial of anthocyanidins and placebo. *J Nutr Environ Med* 2000;10:189-99.
 108. Kaartinen K, Lammi K, Hypen M, Nenonen M, Hanninen O, Rauma A-L. Vegan diet alleviates fibromyalgia symptoms. *Scand J Rheumatol* 2000;29:308-13.
 109. Merchant RE, Carmack CA, Wise CM. Nutritional supplementation with *Chlorella pyrenoidosa* for patients with fibromyalgia syndrome: a pilot study. *Phytother Res* 2000;14:167-73.
 110. Merchant RE, Andre CA, Wise CM. Nutritional supplementation with *Chlorella pyrenoidosa* for fibromyalgia syndrome: A double-blind, placebo-controlled, crossover study. *J Musculoskel Pain* 2001;9:37-54.
 111. Deuster PA, Jaffe RM. A novel treatment for fibromyalgia improves clinical outcomes in a community-based study. *J Musculoskel Pain* 1998;6:133-49.
 112. Massey PB. Reduction of fibromyalgia symptoms through intravenous nutrient therapy: Results of a pilot clinical trial. *Altern Ther Health Med* 2007;13:32-4.
 113. Nielson WR, Walker C, McCain GA. Cognitive behavioral treatment of fibromyalgia syndrome: Preliminary findings. *J Rheumatol* 1992;19:98-103.
 114. Singh BB, Berman BM, Hadhazy VA, Creamer P. A pilot study of cognitive behavioral therapy in fibromyalgia. *Altern Ther Health Med* 1998;4:67-70.
 115. Thieme K, Turk DC, Flor H. Responder criteria for operant and cognitive-behavioral treatment of fibromyalgia syndrome. *Arthritis Rheum* 2007;57:830-6.
 116. Garcia J, Simon MA, Duran M, Cancellor J, Aneiros FJ. Differential efficacy of a cognitive-behavioral intervention versus pharmacological treatment in the management of fibromyalgia syndrome. *Psychol Health Med* 2006;11:984-6.
 117. Mason LW, Goolkasian P, McCain GA. Evaluation of multimodal treatment program for fibromyalgia. *J Behav Med* 1998;21:163-78.
 118. Redondo JR, Justo CM, Moraleda FV, et al. Long-term efficacy of therapy in patients with fibromyalgia: a physical exercise-based program and a cognitive-behavioral approach. *Arthritis Rheum* 2004;51:184-92.
 119. Soares JFF, Grossi G. A randomized, controlled comparison of educational and behavioural interventions for women with fibromyalgia. *Scand J Occup Ther* 2002;9:35-45.
 120. Goldenberg DL, Kaplan KH, Nadeau MG, Brodeur C, Smith S, Schmid CH. A controlled study of a stress-reduction, cognitive-behavioral treatment program in fibromyalgia. *J Musculoskel Pain* 1994;2:53-66.
 121. Mengshoel AM, Komnaes HB, Forre O. The effects of 20 weeks of physical fitness training in female patients with fibromyalgia. *Clin Exp Rheumatol* 1992;10:345-9.
 122. Fors EA, Gotestam KG. Patient education, guided imagery and pain related talk in fibromyalgia coping. *Eur J Psychiatry* 2000;14:233-40.
 123. Nicassio PM, Radojevic V, Weisman MH, et al. A comparison of behavioral and educational interventions for fibromyalgia. *J Rheumatol* 1997;24:2000-7.
 124. Oliver K, Cronan TA, Walen HR, Tomita M. Effects of social support and education on health care costs for patients with fibromyalgia. *J Rheumatol* 2001;28:2711-9.
 125. Vlaeyen JW, Teeken-Gruben NJ, Goossens ME, et al. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. I. Clinical effects. *J Rheumatol* 1996;23:1237-45.
 126. Burckhardt CS, Mannerkorpi K, Hedenberg L, Bjelle A. A

- randomized, controlled clinical trial of education and physical training for women with fibromyalgia. *J Rheumatol* 1994;21:714-20.
127. Cedraschi C, Desmeules J, Rapiti E, et al. Fibromyalgia: a randomised, controlled trial of a treatment programme based on self management. *Ann Rheum Dis* 2004;63:290-6.
 128. Gowans SE, deHueck A, Voss S, Richardson M. A randomized, controlled trial of exercise and education for individuals with fibromyalgia. *Arthritis Care Res* 1999;12:120-8.
 129. King SJ, Wessel J, Bhambhani Y, Sholter D, Maksymowych W. The effects of exercise and education, individually or combined, in women with fibromyalgia. *J Rheumatol* 2002;29:2620-7.
 130. Mannerkorpi K, Nyberg B, Ahlmen M, Ekdahl C. Pool exercise combined with an education program for patients with fibromyalgia syndrome. A prospective, randomized study. *J Rheumatol* 2000;27:2473-81.
 131. Zijlstra TR, van de Laar MAFJ, Bernelot Moens HJ, Taal E, Zakraoui L, Rasker JJ. Spa treatment for primary fibromyalgia syndrome: A combination of thalassotherapy, exercise and patient education improves symptoms and quality of life. *Rheumatology Oxford* 2005;44:539-46.
 132. Lemstra M, Olszynski WP. The effectiveness of multidisciplinary rehabilitation in the treatment of fibromyalgia: a randomized controlled trial. *Clin J Pain* 2005;21:166-74.
 133. Evcik D, Kizilay B, Gokcen E. The effects of balneotherapy on fibromyalgia patients. *Rheumatol Int* 2002;22:56-9.
 134. Gunther V, Mur E, Kinigadner U, Miller C. Fibromyalgia — the effect of relaxation and hydrogalvanic bath therapy on the subjective pain experience. *Clin Rheumatol* 1994;13:573-8.
 135. Yurtkuran M, Celiktas M. A randomized, controlled trial of balneotherapy in the treatment of patients with primary fibromyalgia syndrome. *Phys Med Rehabil Kurortmedizin* 1996;6:109-12.
 136. Bell IR, Lewis DA, Lewis SE, et al. EEG alpha sensitization in individualized homeopathic treatment of fibromyalgia. *Int J Neurosci* 2004;114:1195-220.
 137. Bell IR, Lewis DA, Schwartz GE, et al. Electroencephalographic cordance patterns distinguish exceptional clinical responders with fibromyalgia to individualized homeopathic medicines. *J Altern Complement Med* 2004;10:285-99.
 138. Bell IR, Lewis DA, Brooks AJ, et al. Individual differences in response to randomly assigned active individualized homeopathic and placebo treatment in fibromyalgia: implications of a double-blinded optional crossover design. *J Altern Complement Med* 2004;10:269-83.
 139. Blunt KL, Rajwani MH, Guerriero RC. The effectiveness of chiropractic management of fibromyalgia patients: a pilot study. *J Manipulative Physiol Ther* 1997;20:389-99.
 140. Brattberg G. Connective tissue massage in the treatment of fibromyalgia. *Eur J Pain* 1999;3:235-44.
 141. Field T, Delage J, Hernandez-Reif M. Movement and massage therapy reduce fibromyalgia pain. *J Bodywork Mov Ther* 2003;7:49-52.
 142. Hains G, Hains F. A combined ischemic compression and spinal manipulation in the treatment of fibromyalgia: a preliminary estimate of dose and efficacy. *J Manipulative Physiol Ther* 2000;23:225-30.
 143. Gamber RG, Shores JH, Russo DP. Osteopathic manipulative treatment in conjunction with medication relieves pain associated with fibromyalgia syndrome. *J Am Osteopath Assoc* 2002;102:321-5.
 144. Wennemer HK, Borg-Stein J, Gomba L, et al. Functionally oriented rehabilitation program for patients with fibromyalgia: preliminary results. *Am J Phys Med Rehabil* 2006;85:659-66.
 145. Citak-Karakaya I, Akbayrak T, Demirturk F, Ekici G, Bakar Y. Short and long-term results of connective tissue manipulation and combined ultrasound therapy in patients with fibromyalgia. *J Manip Physiol Ther* 2006;29:524-8.
 146. Astin JA, Berman BM, Bausell B, Lee WL, Hochberg M, Forsys KL. The efficacy of mindfulness meditation plus Qigong movement therapy in the treatment of fibromyalgia: a randomized controlled trial. *J Rheumatol* 2003;30:2257-62.
 147. Kaplan KH, Goldenberg DL, Galvinnadeau M. The impact of a meditation-based stress reduction program on fibromyalgia. *Gen Hosp Psychiatry* 1993;15:284-9.
 148. Grossman P, Tiefenthaler-Gilmer U, Raysz A, Kesper U. Mindfulness training as an intervention for fibromyalgia: Evidence of postintervention and 3-year follow-up benefits in well-being. *Psychother Psychosom* 2007;76:226-33.
 149. Pearl SJ, Lue F, MacLean AW, Heslegrave RJ, Reynolds WJ, Moldofsky H. The effects of bright light treatment on the symptoms of fibromyalgia. *J Rheumatol* 1996;23:896-902.
 150. Gur A, Karakoc M, Nas K, Cevik R, Sarac J, Demir E. Efficacy of low power laser therapy in fibromyalgia: a single-blind, placebo-controlled trial. *Lasers Med Sci* 2002;17:57-61.
 151. Matsutani LA, Marques AP, Ferreira EA, et al. Effectiveness of muscle stretching exercises with and without laser therapy at tender points for patients with fibromyalgia. *Clin Exp Rheumatol* 2007;25:410-5.
 152. Armagan O, Tascioglu F, Ekim A, Oner C. Long-term efficacy of low level laser therapy in women with fibromyalgia: A placebo-controlled study. *J Back Musculoskel Rehabil* 2006;19:135-40.
 153. Assefi NP, Sherman KJ, Jacobsen C, Goldberg J, Smith WR, Buchwald D. A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia. *Ann Intern Med* 2005;143:10-24.
 154. Deluze C, Bosia L, Zirbs A, Chantraine A, Vischer TL. Electroacupuncture in fibromyalgia: results of a controlled trial. *BMJ* 1992;305:1249-52.
 155. Harris RE, Tian X, Williams DA, et al. Treatment of fibromyalgia with formula acupuncture: Investigation of needle placement, needle stimulation, and treatment frequency. *J Altern Complement Med* 2005;11:663-71.
 156. Sprott H. Efficiency of acupuncture in patients with fibromyalgia. *Clin Bull Myofascial Ther* 1998;3:37-43.
 157. Martin DP, Sletten CD, Williams BA, Berger IH. Improvement in fibromyalgia symptoms with acupuncture: Results of a randomized controlled trial. *Mayo Clinic Proc* 2006;81:749-57.
 158. Singh BB, Wu WS, Hwang SH, et al. Effectiveness of acupuncture in the treatment of fibromyalgia. *Alt Ther Health Med* 2006;12:34-41.
 159. Guo X-J, Jia J. Comparison of therapeutic effects on fibromyalgia syndrome between dermal-neurological electric stimulation and electric acupuncture. *Chinese J Clin Rehabil* 2005;9:171-3.
 160. Alfano AP, Taylor AG, Foresman PA, et al. Static magnetic fields for treatment of fibromyalgia: a randomized controlled trial. *J Altern Complement Med* 2001;7:53-64.
 161. Colbert AP, Markov MS, Banerji M, Pilla AA. Magnetic mattress pad use in patients with fibromyalgia: A randomized double-blind pilot study. *J Back Musculoskel Rehabil* 1999;13:19-31.
 162. Alamo MM, Moral RR, Perula de Torres LA. Evaluation of a patient-centred approach in generalized musculoskeletal chronic pain/fibromyalgia patients in primary care. *Patient Educ Couns* 2002;48:23-31.
 163. Almeida TF, Roizenblatt S, Benedito-Silva AA, Tufik S. The effect of combined therapy (ultrasound and interferential current) on pain and sleep in fibromyalgia. *Pain* 2003;104:665-72.
 164. Bennett RM, Burckhardt CS, Clark SR, O'Reilly CA, Wiens AN, Campbell SM. Group treatment of fibromyalgia: A 6 month

- outpatient program. *J Rheumatol* 1996;23:521-8.
165. Biasi G, Badii F, Magaldi M, Moltoni L, Marcolongo R. A new approach in the treatment of fibromyalgia: The use of a copper wire sheet (Telo Cypro TM). *Minerva Med* 1999;90:39-43.
 166. Bosch RE, Saenz MN, Valls EM, Vinolas VS. Study of quality of life of patients with fibromyalgia: impact of a health education programme. *Aten Primaria* 2002;30:16-21.
 167. Broderick JE, Junghaenel DU, Schwartz JE. Written emotional expression produces health benefits in fibromyalgia patients. *Psychosom Med* 2005;67:326-34.
 168. Chesky KS, Russell IJ, Lopez Y, Kondraske GV. Fibromyalgia tender point pain: A double-blind, placebo-controlled pilot study of music vibration using the music vibration table[™]. *J Musculoskel Pain* 1997;5:33-52.
 169. Creamer P, Singh BB, Hochberg MC, Berman BM. Sustained improvement produced by nonpharmacologic intervention in fibromyalgia: Results of a pilot study. *Arthritis Care Res* 2000;13:198-204.
 170. Huuhka MJ, Haanpaa ML, Leinonen EV. Electroconvulsive therapy in patients with depression and fibromyalgia. *Eur J Pain* 2004;8:371-6.
 171. Keel PJ, Bodoky C, Gerhard U, Muller W. Comparison of integrated group therapy and group relaxation training for fibromyalgia. *Clin J Pain* 1998;14:232-8.
 172. Kendall SA, Brolin-Magnusson K, Soren B, Gerdle B, Henriksson KG. A pilot study of body awareness programs in the treatment of fibromyalgia syndrome. *Arthritis Care Res* 2000;13:304-11.
 173. Lukaczer D, Darland G, Tripp M, et al. A pilot trial evaluating Meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia. *Phytother Res* 2005;19:864-9.
 174. Mueller HH, Donaldson CCS, Nelson DV, Layman M. Treatment of fibromyalgia incorporating EEG-driven stimulation: A clinical outcomes study. *J Clin Psychol* 2001;57:933-52.
 175. Fors EA, Sexton H, Gotestam KG. The effect of guided imagery and amitriptyline on daily fibromyalgia pain: A prospective, randomized, controlled trial. *J Psychiatr Res* 2002;36:179-87.
 176. Pfeiffer A, Thompson JM, Nelson A, et al. Effects of a 1.5-day multidisciplinary outpatient treatment program for fibromyalgia — A pilot study. *Am J Phys Med Rehabil* 2003;82:186-91.
 177. Sverdrup B. Use less cosmetics — suffer less from fibromyalgia? *J Womens Health* 2004;13:187-94.
 178. Thieme K, Gromnica-Ihle E, Flor H. Operant behavioral treatment of fibromyalgia: a controlled study. *Arthritis Care Res* 2003;49:314-20.
 179. Worrel LM, Krahn LE, Sletten CD, Pond GR. Treating fibromyalgia with a brief interdisciplinary program: Initial outcomes and predictors of response. *Mayo Clin Proc* 2001;76:384-90.
 180. Menzies V, Taylor AG, Bourguignon C. Effects of guided imagery on outcomes of pain, functional status, and self-efficacy in persons diagnosed with fibromyalgia. *J Altern Complement Med* 2006;12:23-30.
 181. Brockow T, Wagner A, Franke A, Offenbacher M, Resch KL. A randomized controlled trial on the effectiveness of mild water-filtered near-infrared whole-body hyperthermia as an adjunct to a standard multimodal rehabilitation in the treatment of fibromyalgia. *Clin J Pain* 2007;23:67-75.
 182. Fioravanti A, Perpignano G, Tirri G, et al. Effects of mud-bath treatment on fibromyalgia patients: a randomized clinical trial. *Rheumatol Int* 2007;27:1157-61.
 183. Kravitz HM, Esty ML, Katz RS, Fawcett J. Treatment of fibromyalgia syndrome using low-intensity neurofeedback with the Flexyx neurotherapy system: A randomized controlled clinical trial. *J Neurother* 2006;10:41-58.
 184. Gillis ME, Lumley MA, Moseley-Williams A, Leisen JCC, Roehrs T. The health effects of at-home written emotional disclosure in fibromyalgia: A randomized trial. *Pain Clin* 2006;18:167-73.
 185. Eskioglu E, Yazar D, Bal A, Usan HD, Cakci A. Effects of Stanger bath therapy on fibromyalgia. *Clin Rheumatol* 2007;26:691-4.
 186. Hassett AL, Radvansky DC, Vaschillo EG, et al. A pilot study of the efficacy of heart rate variability (HRV) biofeedback in patients with fibromyalgia. *Appl Psychophysiol Biofeedback* 2007;32:1-10.
 187. Rossini M, Di Munno O, Valentini G, et al. Double-blind multicentre trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. *Clin Exp Rheumatol* 2007;25:182-8.
 188. Ko GD, Hum K, Traitses G, Berbrayer D. Effects of topical O24 essential oils on patients with fibromyalgia syndrome: A randomized, placebo controlled pilot study. *J Musculoskel Pain* 2007;15:11-9.
 189. Babu AS, Mathew E, Danda D, Prakash H. Management of patients with fibromyalgia using biofeedback: A randomized control trial. *Indian J Med Sci* 2007;61:455-61.
 190. Chen KW, Hassett AL, Hou F, Staller J, Lichtbroun AS. A pilot study of external Qigong therapy for patients with fibromyalgia. *J Altern Complement Med* 2006;12:851-6.
 191. Donmez A, Karagulle MZ, Tercan N, et al. Spa therapy in fibromyalgia: a randomized controlled clinic study. *Rheumatol Int* 2005;26:168-72.
 192. Fregni F, Gimenes F, Valle AC, et al. A randomized, sham-controlled, proof of principle study of transcranial direct current stimulation for the treatment of pain in fibromyalgia. *Arthritis Rheum* 2006;54:3988-98.
 193. Edinger JD, Wohlgenuth WK, Krystal AD, Rice JR. Behavioral insomnia therapy for fibromyalgia patients. *Arch Intern Med* 2005;165:2527-35.
 194. Teitelbaum JE, Johnson C, St. Cyr J. The use of D-Ribose in chronic fatigue syndrome and fibromyalgia: A pilot study. *J Altern Complement Med* 2006;12:857-62.